Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.
- LGP to acquire 100% of Cannatrek via scheme of arrangement
- Cannatrek shareholders to receive new LGP ordinary shares and convertible preference shares
- Independent Expert concludes scheme is fair, reasonable, and in shareholders’ best interests
- Combined group to operate across Australia and Europe with pro forma FY26 revenue over AUD 100 million
- Scheme meeting scheduled for 10 April 2026 with implementation expected by 1 May 2026
A Strategic Merger in Medicinal Cannabis
Little Green Pharma Ltd (ASX: LGP) has announced its intention to acquire 100% of Cannatrek Ltd through a scheme of arrangement, a move that promises to reshape the Australian medicinal cannabis landscape. The transaction, valued at an indicative pro forma revenue of over AUD 100 million for the combined group in FY26, aims to leverage complementary capabilities across cultivation, manufacturing, distribution, and digital health services.
Scheme Details and Consideration
Under the proposed scheme, Cannatrek shareholders will receive 1.835806 newly issued LGP ordinary shares and 0.727502 unlisted convertible and redeemable preference shares (CV Shares) for each Cannatrek share held. The CV Shares carry a contingent value mechanism, converting into ordinary shares based on future assessments of contingent liabilities between the two companies. This structure provides a risk mitigation feature for shareholders, protecting their interests against unforeseen liabilities.
The scheme requires approval by Cannatrek shareholders, LGP shareholders, and the Federal Court of Australia. The scheme meeting is scheduled for 10 April 2026, with the implementation date anticipated on 1 May 2026, subject to all conditions precedent being met.
Independent Expert’s Endorsement
RSM Corporate Australia Pty Ltd, acting as the Independent Expert, has concluded that the scheme is fair and reasonable and in the best interests of Cannatrek shareholders, assuming no superior proposal emerges. Their valuation analysis, based on capitalisation of future maintainable earnings for Cannatrek and net asset valuation for LGP, supports the proposed exchange ratio and the contingent value mechanism.
The expert report highlights that Cannatrek shareholders will gain liquidity through shares in a listed entity, participate in the combined group’s future growth, and benefit from operational synergies, particularly in the Australian market and European expansion.
Operational and Market Outlook
The combined entity will operate an international, vertically integrated medicinal cannabis business with significant operations in Australia and Europe. Cannatrek’s GMP-certified packaging and national distribution capabilities will complement LGP’s cultivation and manufacturing facilities in Denmark and Western Australia. The merger is expected to accelerate growth in the European market, where regulatory reforms and market expansion present substantial opportunities.
However, the transaction carries risks typical of the sector, including regulatory compliance, integration challenges, market competition, and uncertainties related to the contingent value shares. Shareholders should also consider the illiquidity of the CV Shares until conversion and the potential tax implications of the scheme.
Governance and Shareholder Support
The boards of both companies unanimously recommend the scheme, with key directors collectively holding approximately 22.35% of Cannatrek shares and intending to vote in favour. Voluntary escrow arrangements have been agreed upon by key stakeholders to support share price stability post-implementation.
Investors are encouraged to review the detailed scheme booklet, including the Independent Expert’s Report, and consider the upcoming shareholder meeting as a critical milestone in this transformative transaction.
Bottom Line?
As the medicinal cannabis sector consolidates, LGP’s acquisition of Cannatrek marks a pivotal step towards scale and international growth, but contingent risks and integration hurdles remain key watchpoints.
Questions in the middle?
- How will the contingent value shares convert amid uncertain future liabilities?
- What synergies and cost savings can the combined group realistically achieve post-merger?
- Could regulatory changes in Australia or Europe materially impact the combined group’s growth trajectory?